Paul B Nagib

Paul B Nagib

Auto-generated profile, based on publicly available information

Paul B Nagib

Center for Psychedelic Drug Research and Education, The Ohio State University College of Social Work, Columbus, Ohio, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
ADAlan K Davis
Alan K Davis
ALAdam W Levin
Adam W Levin
PNPaul B Nagib
Paul B Nagib
SAStacey B Armstrong
Stacey B Armstrong
RLRafaelle L Lancelotta
Rafaelle L Lancelotta
Introduction Psilocybin-assisted therapy has shown significant promise in treating the cluster of mood and anxiety symptoms that comprise post-traumatic stress disorder (PTSD) but has yet to be tested specifically in this condition. Furthermore, current pharmacological and psychotherapeutic treatments for PTSD are difficult to tolerate and limited in efficacy, especially in the US Military Veteran (USMV) population. This open-label pilot study will examine the safety and efficacy of two psilocybin administration sessions (15 mg and 25 mg), combined with psychotherapy, among USMVs with severe, treatment resistant PTSD. Methods and analysis We will recruit 15 USMVs with severe, treatment resistant PTSD. Participants will receive one low dose (15 mg) and one moderate/high dose (25 mg) of psilocybin in conjunction with preparatory and post-psilocybin therapy sessions. The primary safety outcome will be the type, severity and frequency of adverse events and suicidal ideation/behaviour, as measured by the Columbia Suicide Severity Rating Scale. The primary outcome measure for PTSD will be the Clinician Administered PTSD Scale-5. The primary endpoint will be 1 month following the second psilocybin administration session, and the total follow-up time will be 6 months. Ethics and dissemination All participants will be required to provide written informed consent. The trial has been authorised by the Ohio State University Institutional Review Board (study number: 2022H0280). Dissemination of results will occur via a peer-reviewed publication and other relevant media. Trial registration number NCT05554094.

11 August 2022 in International Journal of Drug Policy
Verified
Journal Article
Closed access
ALAdam Levin
Adam Levin
PNPaul B Nagib
Paul B Nagib
SDSelina Deiparine
Selina Deiparine
TGThomas Gao
Thomas Gao
JMJustin Mitchell
Justin Mitchell
ADAlan K Davis
Alan K Davis